QDENGA (Takeda Pharmaceuticals Australia Pty Ltd)
Product name
QDENGA
Date registered
Evaluation commenced
Decision date
Approval time
185 (255 working days)
Active ingredients
dengue virus serotype 1, dengue virus serotype 2, dengue virus serotype 3, dengue virus serotype 4
Registration type
NCE/NBE
Indication
QDENGA is indicated for the prevention of dengue disease in individuals from 4 years of age.
The use of this vaccine should be in accordance with official recommendations.